Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- NEJM Publishes Study on Low-dose Echinacea for Colds
Association comments on published study; Dose found ineffective, AHPA notes concern expressed by one of the researchers that the dose may have been too low to be effective for use in colds, suggests dose or brand selection would have improved study quality.
- NEJM Publishes Study on Low-dose Echinacea for Colds
Association comments on published study; Dose found ineffective, AHPA notes concern expressed by one of the researchers that the dose may have been too low to be effective for use in colds, suggests dose or brand selection would have improved study quality.
- NEJM Publishes Study on Low-dose Echinacea for Colds
Association comments on published study; Dose found ineffective, AHPA notes concern expressed by one of the researchers that the dose may have been too low to be effective for use in colds, suggests dose or brand selection would have improved study quality.
- NEJM Publishes Study on Low-dose Echinacea for Colds
Association comments on published study; Dose found ineffective, AHPA notes concern expressed by one of the researchers that the dose may have been too low to be effective for use in colds, suggests dose or brand selection would have improved study quality.
- NEJM Publishes Study on Low-dose Echinacea for Colds
Association comments on published study; Dose found ineffective, AHPA notes concern expressed by one of the researchers that the dose may have been too low to be effective for use in colds, suggests dose or brand selection would have improved study quality.
- Researchers Study Colostrum’s Effect on Bacteria and Virus
Collaborative research project between Sterling Technology, Inc. and South Dakota State University demonstrates that colostral whey concentrate has immune effect, inhibits toxins, and blocks infection.
- Researchers Study Colostrum’s Effect on Bacteria and Virus
Collaborative research project between Sterling Technology, Inc. and South Dakota State University demonstrates that colostral whey concentrate has immune effect, inhibits toxins, and blocks infection.
- Researchers Study Colostrum’s Effect on Bacteria and Virus
Collaborative research project between Sterling Technology, Inc. and South Dakota State University demonstrates that colostral whey concentrate has immune effect, inhibits toxins, and blocks infection.
- Herb Science Group’s Letter Regarding Low Dosage in Echinacea Trial Published in New England Journal of Medicine
The New England Journal of Medicine [NEJM] has published a letter to the editor from the American Botanical Council (written by ABC Founder and Executive Director Mark Blumenthal and Norman R. Farnsworth, PhD, Research Professor of Pharmacognosy and Senior University Scholar at the College of Pharmacy at the University of Illinois at Chicago) regarding the low dosage of Echinacea extracts used in a recent clinical trial. The letter suggested that the dosage administered in the trial may have been too low to produce an appreciable benefit.
- Herb Science Group’s Letter Regarding Low Dosage in Echinacea Trial Published in New England Journal of Medicine
The New England Journal of Medicine [NEJM] has published a letter to the editor from the American Botanical Council (written by ABC Founder and Executive Director Mark Blumenthal and Norman R. Farnsworth, PhD, Research Professor of Pharmacognosy and Senior University Scholar at the College of Pharmacy at the University of Illinois at Chicago) regarding the low dosage of Echinacea extracts used in a recent clinical trial. The letter suggested that the dosage administered in the trial may have been too low to produce an appreciable benefit.
- Herb Science Group’s Letter Regarding Low Dosage in Echinacea Trial Published in New England Journal of Medicine
The New England Journal of Medicine [NEJM] has published a letter to the editor from the American Botanical Council (written by ABC Founder and Executive Director Mark Blumenthal and Norman R. Farnsworth, PhD, Research Professor of Pharmacognosy and Senior University Scholar at the College of Pharmacy at the University of Illinois at Chicago) regarding the low dosage of Echinacea extracts used in a recent clinical trial. The letter suggested that the dosage administered in the trial may have been too low to produce an appreciable benefit.
- Probiotics From Nutraceutix Shown in Clinical Research to Enhance Immune Function
As presented by university researchers at the North American Research Conference on Complementary and Integrative Medicine in Edmonton, probiotic tablets manufactured by Nutraceutix, Inc. were shown to enhance phagocytosis by monocytes and neutrophils in a healthy adult human population.
- Probiotics From Nutraceutix Shown in Clinical Research to Enhance Immune Function
As presented by university researchers at the North American Research Conference on Complementary and Integrative Medicine in Edmonton, probiotic tablets manufactured by Nutraceutix, Inc. were shown to enhance phagocytosis by monocytes and neutrophils in a healthy adult human population.
- Probiotics From Nutraceutix Shown in Clinical Research to Enhance Immune Function
As presented by university researchers at the North American Research Conference on Complementary and Integrative Medicine in Edmonton, probiotic tablets manufactured by Nutraceutix, Inc. were shown to enhance phagocytosis by monocytes and neutrophils in a healthy adult human population.
- Dr. Alex Schauss to Present Immune Health Research at A4M Congress
Alexander Schauss, Ph.D., FACN, will discuss the results of his study that examined the correlation between the unusually low sick rates of a controlled population of Cedar Rapids, Iowa, factory employees and their exposure to an edible fermentation product at the 14th Annual International Congress on Anti-Aging Medicine, Friday, July 14 from 3:50 – 4:50 p.m. in room #27 of the Stephens Convention Center, Chicago.
- Dr. Alex Schauss to Present Immune Health Research at A4M Congress
Alexander Schauss, Ph.D., FACN, will discuss the results of his study that examined the correlation between the unusually low sick rates of a controlled population of Cedar Rapids, Iowa, factory employees and their exposure to an edible fermentation product at the 14th Annual International Congress on Anti-Aging Medicine, Friday, July 14 from 3:50 – 4:50 p.m. in room #27 of the Stephens Convention Center, Chicago.
- Dr. Alex Schauss to Present Immune Health Research at A4M Congress
Alexander Schauss, Ph.D., FACN, will discuss the results of his study that examined the correlation between the unusually low sick rates of a controlled population of Cedar Rapids, Iowa, factory employees and their exposure to an edible fermentation product at the 14th Annual International Congress on Anti-Aging Medicine, Friday, July 14 from 3:50 – 4:50 p.m. in room #27 of the Stephens Convention Center, Chicago.
- Dr. Alex Schauss to Present Immune Health Research at A4M Congress
Alexander Schauss, Ph.D., FACN, will discuss the results of his study that examined the correlation between the unusually low sick rates of a controlled population of Cedar Rapids, Iowa, factory employees and their exposure to an edible fermentation product at the 14th Annual International Congress on Anti-Aging Medicine, Friday, July 14 from 3:50 – 4:50 p.m. in room #27 of the Stephens Convention Center, Chicago.
- Dr. Alex Schauss to Present Immune Health Research at A4M Congress
Alexander Schauss, Ph.D., FACN, will discuss the results of his study that examined the correlation between the unusually low sick rates of a controlled population of Cedar Rapids, Iowa, factory employees and their exposure to an edible fermentation product at the 14th Annual International Congress on Anti-Aging Medicine, Friday, July 14 from 3:50 – 4:50 p.m. in room #27 of the Stephens Convention Center, Chicago.
- Study: Selenomax(R) Suppresses Progression of the Human Immunodeficiency Virus (HIV-1) According to Results Published in Archives of Internal Medicine
Results of a five-year, double-blind, placebo-controlled study conducted by researchers at the University of Miami and published in the January 22 issue of the American Medical Association's Archives of Internal Medicine indicate that daily supplementation with Selenomax(R), Nutrition 21's high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women.
- Study: Selenomax(R) Suppresses Progression of the Human Immunodeficiency Virus (HIV-1) According to Results Published in Archives of Internal Medicine
Results of a five-year, double-blind, placebo-controlled study conducted by researchers at the University of Miami and published in the January 22 issue of the American Medical Association's Archives of Internal Medicine indicate that daily supplementation with Selenomax(R), Nutrition 21's high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women.
- Study: Selenomax(R) Suppresses Progression of the Human Immunodeficiency Virus (HIV-1) According to Results Published in Archives of Internal Medicine
Results of a five-year, double-blind, placebo-controlled study conducted by researchers at the University of Miami and published in the January 22 issue of the American Medical Association's Archives of Internal Medicine indicate that daily supplementation with Selenomax(R), Nutrition 21's high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women.
- Study: Selenomax(R) Suppresses Progression of the Human Immunodeficiency Virus (HIV-1) According to Results Published in Archives of Internal Medicine
Results of a five-year, double-blind, placebo-controlled study conducted by researchers at the University of Miami and published in the January 22 issue of the American Medical Association's Archives of Internal Medicine indicate that daily supplementation with Selenomax(R), Nutrition 21's high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women.
- Study: Selenomax(R) Suppresses Progression of the Human Immunodeficiency Virus (HIV-1) According to Results Published in Archives of Internal Medicine
Results of a five-year, double-blind, placebo-controlled study conducted by researchers at the University of Miami and published in the January 22 issue of the American Medical Association's Archives of Internal Medicine indicate that daily supplementation with Selenomax(R), Nutrition 21's high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women.
- Study Finds Biothera Compounds Enhance Human Immune Cell Function
Researchers at Rhode Island Hospital and the Warren Alpert Medical School at Brown University measured the ability of human neutrophils to kill filamentous Candida albicans, determining that Biothera’s yeast-derived beta 1,3/1,6 glucans (Imprime PGG(TM) and WGP(R) 3-6) enhance the anti-microbial function of the neutrophils.
- Study Finds Biothera Compounds Enhance Human Immune Cell Function
Researchers at Rhode Island Hospital and the Warren Alpert Medical School at Brown University measured the ability of human neutrophils to kill filamentous Candida albicans, determining that Biothera’s yeast-derived beta 1,3/1,6 glucans (Imprime PGG(TM) and WGP(R) 3-6) enhance the anti-microbial function of the neutrophils.
- Study Finds Biothera Compounds Enhance Human Immune Cell Function
Researchers at Rhode Island Hospital and the Warren Alpert Medical School at Brown University measured the ability of human neutrophils to kill filamentous Candida albicans, determining that Biothera’s yeast-derived beta 1,3/1,6 glucans (Imprime PGG(TM) and WGP(R) 3-6) enhance the anti-microbial function of the neutrophils.
- GTC Nutrition Announces Three New Published Studies on NutraFlora scFOS® Prebiotic Fiber
GTC Nutrition today announced the publication of three new studies relating to NutraFlora® short-chain fructooligosaccharides (scFOS®) prebiotic fiber and immune health. These studies are published in the World Journal of Gastroenterology, Journal of Animal Physiology and Animal Nutrition and the Journal of Agricultural and Food Chemistry.
- GTC Nutrition Announces Three New Published Studies on NutraFlora scFOS® Prebiotic Fiber
GTC Nutrition today announced the publication of three new studies relating to NutraFlora® short-chain fructooligosaccharides (scFOS®) prebiotic fiber and immune health. These studies are published in the World Journal of Gastroenterology, Journal of Animal Physiology and Animal Nutrition and the Journal of Agricultural and Food Chemistry.
- GTC Nutrition Announces Three New Published Studies on NutraFlora scFOS® Prebiotic Fiber
GTC Nutrition today announced the publication of three new studies relating to NutraFlora® short-chain fructooligosaccharides (scFOS®) prebiotic fiber and immune health. These studies are published in the World Journal of Gastroenterology, Journal of Animal Physiology and Animal Nutrition and the Journal of Agricultural and Food Chemistry.
- Study Finds Biothera's Imprime PGG Increases Efficacy of Erbitux against Non-Small Cell Lung Cancer
Preclinical research published in Cancer Research, suggests that Imprime PGG(TM) may increase the efficacy of Erbitux(R) for the treatment of non-small cell lung cancer and potentially other cancers that express epidermal growth factor receptor (EGFR) on their cell surface.
- Study Finds Biothera's Imprime PGG Increases Efficacy of Erbitux against Non-Small Cell Lung Cancer
Preclinical research published in Cancer Research, suggests that Imprime PGG(TM) may increase the efficacy of Erbitux(R) for the treatment of non-small cell lung cancer and potentially other cancers that express epidermal growth factor receptor (EGFR) on their cell surface.
- Study Finds Biothera's Imprime PGG Increases Efficacy of Erbitux against Non-Small Cell Lung Cancer
Preclinical research published in Cancer Research, suggests that Imprime PGG(TM) may increase the efficacy of Erbitux(R) for the treatment of non-small cell lung cancer and potentially other cancers that express epidermal growth factor receptor (EGFR) on their cell surface.
- Study Demonstrates that AHCC® Enhances Immune System by Increasing the Production of Key Dendritic Cells
A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells.
- Study Demonstrates that AHCC® Enhances Immune System by Increasing the Production of Key Dendritic Cells
A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells.
- Study Demonstrates that AHCC® Enhances Immune System by Increasing the Production of Key Dendritic Cells
A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells.
- Study Demonstrates that AHCC® Enhances Immune System by Increasing the Production of Key Dendritic Cells
A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells.
- Study Demonstrates that AHCC® Enhances Immune System by Increasing the Production of Key Dendritic Cells
A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells.
- Study Demonstrates that AHCC® Enhances Immune System by Increasing the Production of Key Dendritic Cells
A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells.
- Study Demonstrates that AHCC® Enhances Immune System by Increasing the Production of Key Dendritic Cells
A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells.
- Study Demonstrates that AHCC® Enhances Immune System by Increasing the Production of Key Dendritic Cells
A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs). DCs are a key part of the immune system responsible for presenting foreign substances to other immune system cells.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Toronto, Canada (15 August 2006) - glisodin.org, an international research community dedicated to the Glisodin SOD/gliadin complex, announces the inclusion of a key study on Glisodin and immune compromised individuals at the AIDS 2006 - XVI International AIDS Conference, August 13-18 2006, held in Toronto. In this study, Glisodin was shown to restore the circulating antioxidant capacities, including Superoxide Dismustase (SOD), in the Glisodin group as compared to no change in the control and placebo group. SOD is an endogenous antioxidant produced by the body at the cellular level, providing the first line of defense against oxidative stress.
"The effects of an orally effective SOD (Glisodin) on AIDS West African patients in a randomized double-blinded clinical study," was conducted by French and American Researchers with HIV patients in the Ivory Coast. http://www.iasociety.org/abstract/show.asp?abstract_id=2180443.
Acquired immunodeficiency syndrome (AIDS) is associated with oxidative stress that is responsible for the development of pro-inflammatory disorders and organ failures. In addition, usual anti-retroviral therapies induce important oxidative disorders in promoting mitochondrial swelling, and thus contribute to the development of oxidative disorders in HIV/AIDS infected patients.
The cumulative pro-oxidant effects of the infectious process itself and the potential toxicity of the anti-retroviral therapies could be the origin of most of the inflammatory and toxicological disorders observed in these patients. The objectives of the study were to assess the effects of orally effective SOD/gliadin (Glisodin) on AIDS patients.
In the study, thirty-five AIDS patients were blindly divided into three groups: 1. Placebo (n=12); 2. Non-protected SOD (1000 IU/day, n = 12) as a control; and 3. SOD/Gliadin (Glisodin) product (1000 IU /per day, n = 11). The study products were to be taken once daily, orally for 21 days. Prior to the study, it was first documented that the circulating antioxidant status and the endogenous SOD levels of the study population (n=35) was significantly decreased (p < 0.01) compared to non-infected healthy West African donors.
A statistically significant restoration of the circulating antioxidant capacities was observed in AIDS patients (n = 11) taking the SOD/Gliadin (Glisodin) product: SOD1 activity (p<0.01), Gpx activity (p<0.05), total antioxidant status (p<0.001) and significantly reduced b2-microglobulin plasma concentration (p < 0.01) , during the same period no significant effects were observed for the Non-protected SOD and Placebo groups. This demonstrates that only the SOD/Gliadin preparation was able to efficiently support the antioxidant defenses in AIDS patients.
The authors concluded, "The statistically significant antioxidant restoration and decreased b2-microglobulin concentration in Glisodin-supplemented AIDS patients suggests a beneficial effect of the Glisodin product in HIV/AIDS patients. These results suggest that these patients will be prepared for a better compliance and a better efficacy to the anti-retroviral therapy."
www.Glisodin.org provides research links and studies establishing proof of concept in vitro and in vivo, and efficacy in animal and human models. Human studies include protection of mitochondrial DNA, inhibition of isoprostanes, protection against UV radiation and sun allergy, and other therapeutic benefits of Glisodin supplementation.
International contact: Francois Vix [33] 1 53 98 85 00
U.S. Contact: Eric Anderson
480-227-9383
eric@glisodin.org
# # #
glisodin.org is a research community dedicated to the understanding and advancement of glisodin SOD/gliadin complex. www.glisodin.org |